These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31122310)

  • 1. Current management and use of oral immunotherapy in the United States for patients with peanut allergy.
    Blaiss MS; Tilles S; Petroni D; Zigmont E; Cassese M; Kwak B; Georgitseas N; Liebermann J
    Allergy Asthma Proc; 2019 Jul; 40(4):214-220. PubMed ID: 31122310
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of life improves significantly after real-world oral immunotherapy for children with peanut allergy.
    Blackman AC; Staggers KA; Kronisch L; Davis CM; Anagnostou A
    Ann Allergy Asthma Immunol; 2020 Aug; 125(2):196-201.e1. PubMed ID: 32278075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.
    Wasserman RL; Factor JM; Baker JW; Mansfield LE; Katz Y; Hague AR; Paul MM; Sugerman RW; Lee JO; Lester MR; Mendelson LM; Nacshon L; Levy MB; Goldberg MR; Elizur A
    J Allergy Clin Immunol Pract; 2014; 2(1):91-6. PubMed ID: 24565775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memory and naïve gamma delta regulatory T-cell gene expression in the first 24-weeks of peanut oral immunotherapy.
    Anvari S; Watkin L; Rajapakshe K; Hassan O; Schuster K; Coarfa C; Davis CM
    Clin Immunol; 2021 Sep; 230():108820. PubMed ID: 34365017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future treatments for peanut allergy.
    Lee T; Edwards-Salmon S; Vickery BP
    Clin Exp Allergy; 2023 Jan; 53(1):10-24. PubMed ID: 36222329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peanut allergy: risk factors, immune mechanisms, and best practices for oral immunotherapy success.
    Tirumalasetty J; Barshow S; Kost L; Morales L; Sharma R; Lazarte C; Nadeau KC
    Expert Rev Clin Immunol; 2023; 19(7):785-795. PubMed ID: 37129440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Economic Analysis of a Peanut Oral Immunotherapy Study in Children.
    Shaker MS
    J Allergy Clin Immunol Pract; 2017; 5(6):1707-1716. PubMed ID: 28606784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world attitudes among allergists/immunologists regarding oral immunotherapy and preferred terminology.
    Chipps BE; Ciaccio CE; Rosén K; Haselkorn T; Zigmont E; Casale TB
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):721-723.e9. PubMed ID: 30557711
    [No Abstract]   [Full Text] [Related]  

  • 9. Current Trend in Immunotherapy for Peanut Allergy.
    Joo Chan C; Richardo T; Lim RLH
    Int Rev Immunol; 2018; 37(6):279-290. PubMed ID: 30638084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis.
    Shaker M; Greenhawt M
    JAMA Netw Open; 2019 May; 2(5):e193242. PubMed ID: 31050778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Cost-Effectiveness of Preschool Peanut Oral Immunotherapy in the Real-World Setting.
    Shaker M; Chan ES; Protudjer JLP; Soller L; Abrams EM; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2876-2884.e4. PubMed ID: 33744474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in management of peanut allergy between allergists and pediatricians.
    Manious M; Atalla J; Erwin E; Stukus D; Mikhail I
    Ann Allergy Asthma Immunol; 2020 May; 124(5):512-513. PubMed ID: 32006704
    [No Abstract]   [Full Text] [Related]  

  • 13. Current opinion and review on peanut oral immunotherapy.
    Deol S; Bird JA
    Hum Vaccin Immunother; 2014; 10(10):3017-21. PubMed ID: 25483680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on peanut allergy: Prevention and immunotherapy.
    Cook QS; Kim EH
    Allergy Asthma Proc; 2019 Jan; 40(1):14-20. PubMed ID: 30582491
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of Anaphylaxis During Peanut Oral Immunotherapy.
    Szafron V; Anagnostou A
    Curr Allergy Asthma Rep; 2023 Jan; 23(1):21-27. PubMed ID: 36445653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents.
    Brandström J; Vetander M; Sundqvist AC; Lilja G; Johansson SGO; Melén E; Sverremark-Ekström E; Nopp A; Nilsson C
    Clin Exp Allergy; 2019 Oct; 49(10):1328-1341. PubMed ID: 31329313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximum Dose Food Challenges Reveal Transient Sustained Unresponsiveness in Peanut Oral Immunotherapy (POIMD Study).
    Davis CM; Anagnostou A; Devaraj S; Vita DT; Rivera F; Pitts K; Hearrell M; Minard C; Guffey D; Gupta M; Watkin L; Orange JS; Anvari S
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):566-576.e6. PubMed ID: 34890827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative interviews to understand health care providers' experiences of prescribing licensed peanut oral immunotherapy.
    Anagnostou A; Lawrence C; Tilles SA; Laubach S; Donelson SM; Yassine M; Nowak-Wegrzyn A
    BMC Res Notes; 2022 Aug; 15(1):273. PubMed ID: 35941597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events associated with peanut oral immunotherapy in children - a systematic review and meta-analysis.
    Grzeskowiak LE; Tao B; Knight E; Cohen-Woods S; Chataway T
    Sci Rep; 2020 Jan; 10(1):659. PubMed ID: 31959857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy.
    Sharma V; Jobrack J; Cerenzia W; Tilles S; Ryan R; Sih-Meynier R; Zeitler S; Manning M
    PLoS One; 2020; 15(12):e0241648. PubMed ID: 33270629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.